New combo therapy aims to stop rare, aggressive skin cancer from coming back
NCT ID NCT04318717
Summary
This study is testing whether a combination of targeted radiation and an immunotherapy drug (pembrolizumab) can help prevent mucosal melanoma from returning after it has been surgically removed. The treatment is for adults with mucosal melanoma of the head and neck who have had surgery but have not yet received radiation. Researchers will compare the results to historical data to see if the combination is more effective than radiation alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.